Nebulised treprostinil prodrug - Insmed

Drug Profile

Nebulised treprostinil prodrug - Insmed

Alternative Names: INS-1009

Latest Information Update: 04 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Insmed
  • Class Antihypertensives; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pulmonary arterial hypertension

Most Recent Events

  • 03 Sep 2016 Pharmacodynamics data from preclinical studies in Pulmonary arterial hypertension presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
  • 03 Sep 2016 Pharmacokinetics data from a phase I trial in Healthy volunteers presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
  • 01 Sep 2016 Clinical data from a phase I trial in Pulmonary arterial hypertension (In volunteers) presented at the 26th Annual Congress of the European Respiratory Society (ERS-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top